In a landmark move for cancer treatment, China’s National Medical Products Administration has approved the world’s first chimeric antigen receptor T-cell therapy specifically designed to target solid tumors. The decision marks a major breakthrough for a class of treatment that has so far been limited to blood cancers, offering new hope to patients with advanced solid malignancies.
The newly approved therapy, CT041, is a CAR-T cell treatment developed by biotech firm CARsgen. It targets CLDN18.2, a protein commonly found on the surface of gastric, pancreatic, and other gastrointestinal cancers. In clinical trials, the therapy demonstrated a response rate of 61.1% in patients with advanced gastric or gastroesophageal junction cancer who had previously failed two or more lines of therapy. This is a significant improvement over standard chemotherapy options in the same setting.
Unlike CAR-T therapies for blood cancers, which target CD19 or BCMA proteins on immune cells, solid tumors present unique challenges. The tumor microenvironment can suppress T-cell activity, and identifying a safe, tumor-specific target has been difficult. CT041 overcomes some of these hurdles by using a humanized antibody that binds tightly to CLDN18.2, which is expressed at high levels in tumor cells but minimally in healthy tissues. This design helps reduce off-target effects while maintaining potent anticancer activity.
What This Means for Patients and Global Drug Development
For patients in China, the approval opens an immediate treatment option. The therapy is indicated for adults with CLDN18.2-positive advanced gastric or gastroesophageal junction cancer who have exhausted standard therapies. The approval is conditional, meaning CARsgen must confirm the benefit in a larger phase 3 trial within a set timeframe. Still, the decision accelerates access for a population with very few effective late-line options.
The approval also raises the question of whether regulators in the United States and Europe will follow. CARsgen has already initiated a phase 2 trial in the U.S., and the company plans to seek Food and Drug Administration approval based on those results. If successful, CT041 could become the first CAR-T therapy approved for solid tumors in Western markets. The company is also exploring the therapy in other CLDN18.2-positive cancers, including pancreatic cancer, which has historically been difficult to treat.
Looking ahead, the approval signals a shift in the CAR-T landscape. While blood cancer treatments have dominated the field, solid tumors represent more than 90% of all cancers. The success of CT041 may pave the way for a new generation of cell therapies targeting other solid tumor antigens. Researchers and patients alike will be watching closely as data from ongoing trials emerge, hopeful that this is the first of many such approvals to come.